The Pharmaceutical Research and Manufacturers of America (PhRMA) today released statements in that were critical of bills in the House and Senate aimed at curbing abusive patent litigation.
Kenneth C. Frazier, chairman and CEO of Merck & Co., Inc., was elected chairman of the Board...
PhRMA honored 13 employees from 12 biopharmaceutical companies as “We Work For Health Champions...
PhRMA launched a new Innovation Hub to showcase the latest data and research on...
Eli Lilly and Company today announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
PhRMA Issues Statement on FDA Draft Guidance on Labeling for Products Approved Under the Accelerated Approval PathwayMay 30, 2014 3:53 pm | News | Comments
The Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, PhD, issued the following statement on the Food and Drug Administration (FDA) draft guidance on labelling for human prescription drug and biologics approved under the Accelerated Approval pathway.
The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani today released a statement on the cost and value of medicines.
The Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President and General Counsel Mit Spears issued a statement on the patent legislation pending in the U.S. Senate.
By joining the portal, Bayer HealthCare is supporting efforts of the European Medicines Agency (EMA) to increase the transparency of data from clinical studies. As a member company of the pharmaceutical trade associations EFPIA and PhRMA, Bayer is following their declared principles on responsible clinical trial data sharing.
Gov. Terry McAuliffe this week announced the state's support for the "I'm In" campaign launched by the Pharmaceutical Research and Manufacturers of America and the National Minority Quality Forum.
The Special 301 process garners the high-level attention from our trading partners necessary to redress intellectual property violations and market access concerns within individual markets and to send signals to other U.S. trading partners that protecting American intellectual property is important not only to the U.S. economy but also to patients across the globe.
Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the trade association’s annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.
The I'm In campaign will raise awareness about the importance of clinical research and encourage greater participation by diverse patient populations to help researchers develop potential new life-saving medicines.
Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.
Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement regarding the President's State of the Union address.
America’s biopharmaceutical research companies are developing 452 new medicines for rare diseases, including genetic disorders, neurological conditions, infectious diseases and autoimmune disorders, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) endorsed "Principles for Responsible Clinical Trial Data Sharing: Our Commitment to Patients and Researchers."
The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Lori Reilly will become Executive Vice President of Policy and Research, effective June 7, 2013. She succeeds Rick Smith, who will retire after 11 years of service with PhRMA. Reilly will report directly to PhRMA President and CEO John Castellani and serve as a member of the PhRMA Management Committee.
A new report says the more than 550 clinical trials of new medicines in Maine since 1999 support thousands of jobs and millions of dollars in federal and state taxes. Gov. Paul LePage was joined by business and drug industry leaders at Friday's news conference who presented the Pharmaceutical Research and Manufacturers of America's report.
Celgene's Robert J. Hugin Becomes PhRMA Board Chairman; Ian C. Read, Kenneth C. Frazier Assume New PostsApril 12, 2013 1:40 pm | News | Comments
Robert J. Hugin, chairman and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Ian C. Read, president and CEO of Pfizer Inc, as chairman-elect of the PhRMA Board of Directors, and Kenneth C. Frazier, Chairman, President and CEO of Merck & Co, Inc., as Board treasurer.
Global Pharmaceutical Industry Calls for Broad-Based Cooperation to Fight Online Sales of Counterfeit Medicines Around the WorldJuly 24, 2012 4:18 am | News | Comments
The global pharmaceutical industry has unveiled recommendations to tackle the growing public health threat of counterfeit or fake medicines. The industry's call for increased public awareness and crackdown on makers of the unsafe products comes as a group of private U.S. companies launches the Center for Safe Internet Pharmacies (CSIP) initiative to target illegal Internet pharmacies.
Investment in research and development by members of the Pharmaceutical Research and Manufacturers of America remained strong at $49.5 billion in 2011, as the sector adapts to meet the challenges of evolving science, a changing marketplace and a difficult economic environment.
WASHINGTON (AP) — States cannot stop drug manufacturers and data-mining companies from using information about the prescription drugs individual doctors like to prescribe, the Supreme Court ruled Thursday.
Christopher Viehbacher, chief executive officer of sanofi-aventis, became chairman of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) today upon the resignation of Jeffrey B. Kindler of Pfizer.
Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows
Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.
Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that John J. Castellani will assume the role of President and Chief Executive Officer, effective September 1, 2010. Mr. Castellani joins PhRMA after more than nine years as President and CEO of Business Roundtable, a leading association of corporate chief executive officers.
NEW YORK (AP) — The pharmaceutical industry lobby spent $7 million in the first quarter as it lobbied the federal government on issues that included regulation of generic versions of biotech drugs, according to a recent federal filing.
The U.S. drug industry fended off price curbs and other hefty restrictions in President Barack Obama's health care law even as it prepares for plenty of new business when an estimated 32 million uninsured Americans gain health coverage.
- Page 1